We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.
On Thursday, Eli Lilly and Company's (NYSE:LLY) price target was raised to $957 from the previous $925 by Jefferies, while the firm maintained a Buy rating on the pharmaceutical company's shares.
Tim Smith has 20+ years of experience in the financial services industry, both as a writer and as a trader. Eli Lilly shares rose in extended-hours trading on Monday after a panel of independent ...
Core PCE Inflation Matches Estimates for AprilFri, 31 May 2024 12:48:04 GMT Euro Area Inflation Rises to 2.6%, Core CPI Jumps to 2.9%Fri, 31 May 2024 12:23:10 GMT German Retail Sales Slide by 1.2% ...
Eli Lilly (LLY) is riding high on its diabetes and weight-loss treatments Mounjaro and Zepbound — which Wall Street estimates could net the company $13.5 billion in 2024. "It's not just a flash ...
, opens new tab executive said on Monday that more patients are paying the full list price of its obesity drug Zepbound than those who had paid for its predecessor Mounjaro. Patrik Jonsson ...
Advisers to the Food and Drug Administration voted 11-0 on Monday to recommend the approval of a drug for early Alzheimer’s disease made by Eli Lilly — ruling that the treatment’s ability to ...
A Food and Drug Administration advisory panel on Monday endorsed the experimental Alzheimer's drug donanemab, which studies showed slowed early stages of the fatal mind-robbing disease. The ...
Eli Lilly & Co.’s drug for Alzheimer’s has benefits that outweigh its risks, US drug regulatory advisers said, bringing the treatment’s long path to the market closer to a successful end.
On Monday, a panel of independent advisers to the US Food and Drug Administration voted to endorse Eli Lilly’s drug donanemab, a monoclonal antibody designed to slow the progression of early ...
On Thursday, Eli Lilly and Company's (NYSE:LLY) price target was raised to $957 from the previous $925 by Jefferies, while the firm maintained a Buy rating on the pharmaceutical company's shares. The ...